XGN — Exagen Inc.

Exagen Inc. (XGN) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: Q3 revenue reached $17.2 million, the highest in the company's history, marking a nearly 40% increase year-over-year and over 25% growth compared to Q3 2024.
• Year-to-Date Revenue: Approximately $50 million, reflecting a 19% increase year-to-date, driven by an 8% growth in testing volume and a 9% increase in average selling price (ASP).
• ASP: Trailing 12-month ASP for AVISE CTD testing rose to $441, a 9% year-over-year increase, although ASP growth has been slower than anticipated.
• Gross Margin: Gross margin for Q3 was just over 58%, up 260 basis points from the previous year, but down from over 60% in Q3 2024.
• Net Loss: Reported net loss of $7 million, compared to $5 million in the prior year, influenced by $3 million in noncash expenses related to a new debt facility.
• Cash Position: Ended Q3 with $35.7 million in cash and cash equivalents, up from $30 million at the end of Q2.

2. Strategic Updates and Business Highlights:

• Product Launches: Successfully launched assays for anti-PAD4 antibodies, enhancing the rheumatoid arthritis biomarker portfolio. This innovation is expected to improve clinical outcomes and differentiate Exagen's offerings.
• Volume Growth: Achieved the highest testing volume recorded for Q3, with continued strong performance into October, indicating a positive trend for Q4.
• Sales Expansion: Increased sales territories from 42 to 45, with new territories contributing to growth. The company remains focused on profitable growth and expanding its sales force strategically.
• Pharma Services Revenue: Generated nearly $800,000 in Q3, with a year-to-date total of $1.2 million, reflecting significant growth from $100,000 in the previous year.

3. Forward Guidance and Outlook:

• Revenue Guidance: Exagen expects to achieve $65 million to $70 million in revenue for 2025, with potential for cash flow positivity at the high end of this range, although sustained cash flow positivity may be pushed to 2026.
• ASP Expectations: The company aims for continued ASP growth, although recent challenges may temper expectations for immediate increases.

4. Bad News, Challenges, or Points of Concern:

• ASP Headwinds: The loss of a high ASP direct bill account impacted current ASP figures, with a blended ASP headwind of over $20. The transition to a standard commercial insurance payer mix is expected to take time.
• Denial Rates: Higher-than-expected denial rates for new biomarkers due to medical policy issues and coding challenges. Initial denials have been more frequent than anticipated, impacting revenue recognition.
• Operating Expenses: Increased operating expenses to $13.2 million from $11.6 million in Q3 2024, driven by R&D and sales expansion costs. The company expects expenses to remain stable in the near term.

5. Notable Q&A Insights:

• Sales Rep Productivity: New sales representatives typically take 6 to 9 months to reach full productivity. The company is optimistic about the performance of recently expanded territories.
• ASP Projections: Management remains confident in achieving a long-term ASP target of $500, despite recent setbacks. They anticipate gradual improvements as they establish payment histories for new biomarkers.
• Pharma Business Growth: The pharma services segment is expected to grow, with opportunities for further partnerships and projects, although revenue recognition may be lumpy.
• Direct Bill Account Transition: The transition from a direct bill to a commercial insurance model has caused temporary disruptions, but volumes are recovering, and management is optimistic about future growth.

Overall, Exagen reported a strong Q3 performance with record revenue and volume growth, but faces challenges related to ASP and reimbursement dynamics. The company remains focused on strategic expansions and innovation in the autoimmune diagnostics space.